MX2011010061A - Biomarcador para monitorear pacientes. - Google Patents
Biomarcador para monitorear pacientes.Info
- Publication number
- MX2011010061A MX2011010061A MX2011010061A MX2011010061A MX2011010061A MX 2011010061 A MX2011010061 A MX 2011010061A MX 2011010061 A MX2011010061 A MX 2011010061A MX 2011010061 A MX2011010061 A MX 2011010061A MX 2011010061 A MX2011010061 A MX 2011010061A
- Authority
- MX
- Mexico
- Prior art keywords
- biomarcator
- immunotherapy
- monitor patients
- methods
- field
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09305256 | 2009-03-24 | ||
| PCT/EP2010/053755 WO2010108908A1 (en) | 2009-03-24 | 2010-03-23 | Biomarker for monitoring patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011010061A true MX2011010061A (es) | 2011-11-18 |
Family
ID=42153802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011010061A MX2011010061A (es) | 2009-03-24 | 2010-03-23 | Biomarcador para monitorear pacientes. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20120028279A1 (https=) |
| EP (1) | EP2411815B1 (https=) |
| JP (1) | JP5774578B2 (https=) |
| KR (1) | KR20110138354A (https=) |
| CN (1) | CN102362184B (https=) |
| AU (1) | AU2010227611B2 (https=) |
| BR (1) | BRPI1009892A2 (https=) |
| CA (1) | CA2756133A1 (https=) |
| CO (1) | CO6450670A2 (https=) |
| DK (1) | DK2411815T3 (https=) |
| ES (1) | ES2555858T3 (https=) |
| HU (1) | HUE026194T2 (https=) |
| IL (1) | IL214611A (https=) |
| MX (1) | MX2011010061A (https=) |
| NZ (1) | NZ595290A (https=) |
| RU (1) | RU2542435C2 (https=) |
| SG (2) | SG2014014021A (https=) |
| TW (1) | TWI470225B (https=) |
| WO (1) | WO2010108908A1 (https=) |
| ZA (1) | ZA201106890B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010270313B2 (en) | 2009-07-10 | 2014-05-22 | Transgene Sa | Biomarker for selecting patients and related methods |
| EP3605090A1 (en) * | 2012-05-23 | 2020-02-05 | F. Hoffmann-La Roche AG | Selection method for therapeutic agents |
| US10799567B2 (en) * | 2014-04-11 | 2020-10-13 | Globeimmune, Inc. | Yeast-based immunotherapy and type I interferon sensitivity |
| EP3466446B1 (en) * | 2016-03-29 | 2023-12-27 | Karydo Therapeutix, Inc. | Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
| DE3642912A1 (de) | 1986-12-16 | 1988-06-30 | Leybold Ag | Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer |
| US6222020B1 (en) | 1987-01-07 | 2001-04-24 | Imperial Cancer Research Technology Limited | Antigens derived from the core protein of the human mammary epithelial mucin |
| FR2632863B2 (fr) | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
| US5100587A (en) | 1989-11-13 | 1992-03-31 | The United States Of America As Represented By The Department Of Energy | Solid-state radioluminescent zeolite-containing composition and light sources |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| DE69233158T2 (de) | 1991-03-07 | 2004-05-13 | Connaught Technology Corp., Greenville | Gentechnologisch hergestellter stamm für impfstoffe |
| US5179993A (en) | 1991-03-26 | 1993-01-19 | Hughes Aircraft Company | Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid |
| US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| ATE509102T1 (de) | 1994-07-15 | 2011-05-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
| US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
| CA2261989C (en) | 1996-07-25 | 2008-09-30 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| FR2751879B1 (fr) | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
| ATE298098T1 (de) * | 1997-02-06 | 2005-07-15 | Univ Dublin | Elektrochromes system |
| EP1012276A2 (en) | 1997-02-24 | 2000-06-28 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| EP0958826A4 (en) * | 1997-03-07 | 2001-04-11 | Akira Hayashi | IMMUNOTHERAPEUTIC AGAINST CANCER CONTAINING NUCLEOID INGREDIENTS OF BACTERIA AS AN ACTIVE INGREDIENT |
| JPH10306029A (ja) * | 1997-03-07 | 1998-11-17 | Akira Hayashi | 細菌の菌体成分を有効成分とする癌免疫療法剤 |
| US20030138454A1 (en) * | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| GB9819726D0 (en) | 1998-09-11 | 1998-11-04 | Advanced Environmental Enginee | Vapour recovery system |
| US20020037274A1 (en) | 1998-10-26 | 2002-03-28 | Angelica Williams | Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
| FR2787465A1 (fr) | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
| CA2362367C (en) | 1999-02-04 | 2004-08-03 | Geron Corporation | Telomerase reverse transcriptase transcriptional regulatory sequences |
| EP1155120B1 (fr) | 1999-02-22 | 2006-07-05 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| ES2288488T3 (es) | 1999-11-15 | 2008-01-16 | Onyx Pharmaceuticals, Inc. | Adenovirus oncoliticos. |
| AUPQ520800A0 (en) | 2000-01-21 | 2000-02-17 | Alfred Hospital | Prime-boost vaccination strategy |
| PL212047B1 (pl) | 2000-11-23 | 2012-08-31 | Bavarian Nordic As | Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania |
| ES2424131T3 (es) * | 2001-03-27 | 2013-09-27 | Oncothyreon Inc. | Vacuna para modular respuestas inmunitarias entre T1 y T2 |
| GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| AT500647A1 (de) * | 2002-05-21 | 2006-02-15 | Igeneon Krebs Immuntherapie | Verwendung eines impfstoffes |
| EP1509244B1 (en) * | 2002-06-06 | 2011-07-27 | Immunicum AB | New method and composition for producing a cellular allogeneic vaccine |
| PT2241325E (pt) | 2002-10-29 | 2012-04-12 | Coley Pharm Gmbh | Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c |
| US20040197304A1 (en) * | 2003-04-01 | 2004-10-07 | The Procter & Gamble Company And Alimentary Health, Ltd. | Methods of determining efficacy of treatments of inflammatory diseases of the bowel |
| FR2855758B1 (fr) | 2003-06-05 | 2005-07-22 | Biomerieux Sa | Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique |
| CN1889963A (zh) * | 2003-10-10 | 2007-01-03 | 宝德杰克特疫苗有限公司 | 方法 |
| FR2862648B1 (fr) | 2003-11-21 | 2006-02-03 | Biomerieux Sa | Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c |
| AU2005205441A1 (en) * | 2004-01-13 | 2005-07-28 | Dnavec Research Inc. | Gene therapy for tumor using minus-strand RNA virus vector encoding immunostimulating cytokine |
| WO2005118884A1 (en) * | 2004-05-28 | 2005-12-15 | The United States Of America As Represented By The Secretary Of The Navy | A method for the rapid diagnosis of infectious disease by detection and quantitation of microorganism induced cytokines |
| CN101035901A (zh) * | 2004-07-22 | 2007-09-12 | 细胞基因系统有限公司 | 腺病毒载体中转基因的插入 |
| ES2389562T3 (es) * | 2004-10-25 | 2012-10-29 | Statens Seruminstitut | Antígenos de Chlamydia trachomatis para uso en vacuna y diagnóstico |
| EP1874342B1 (en) * | 2005-04-26 | 2018-06-06 | Eisai R&D Management Co., Ltd. | Compositions and methods for cancer immunotherapy |
| PL1896051T3 (pl) * | 2005-06-28 | 2015-04-30 | Oncothyreon Inc | Sposób leczenia pacjentów szczepionką glikoproteiny mucynowej (muc-1) |
| JP2009526991A (ja) * | 2006-02-17 | 2009-07-23 | パオロ・ラ・コッラ | 増殖性疾患及び／又はコンホメーション病の診断方法 |
| JP5382529B2 (ja) * | 2007-09-10 | 2014-01-08 | 独立行政法人理化学研究所 | ヒト樹状細胞の評価方法およびヒト細胞免疫療法剤 |
-
2010
- 2010-03-23 SG SG2014014021A patent/SG2014014021A/en unknown
- 2010-03-23 CN CN201080013134.7A patent/CN102362184B/zh not_active Expired - Fee Related
- 2010-03-23 WO PCT/EP2010/053755 patent/WO2010108908A1/en not_active Ceased
- 2010-03-23 NZ NZ595290A patent/NZ595290A/xx not_active IP Right Cessation
- 2010-03-23 BR BRPI1009892A patent/BRPI1009892A2/pt not_active IP Right Cessation
- 2010-03-23 DK DK10709742.0T patent/DK2411815T3/en active
- 2010-03-23 SG SG2011068335A patent/SG174507A1/en unknown
- 2010-03-23 RU RU2011142612/15A patent/RU2542435C2/ru not_active IP Right Cessation
- 2010-03-23 US US13/260,223 patent/US20120028279A1/en not_active Abandoned
- 2010-03-23 AU AU2010227611A patent/AU2010227611B2/en not_active Ceased
- 2010-03-23 CA CA2756133A patent/CA2756133A1/en not_active Abandoned
- 2010-03-23 ES ES10709742.0T patent/ES2555858T3/es active Active
- 2010-03-23 KR KR1020117022284A patent/KR20110138354A/ko not_active Abandoned
- 2010-03-23 HU HUE10709742A patent/HUE026194T2/en unknown
- 2010-03-23 EP EP10709742.0A patent/EP2411815B1/en not_active Not-in-force
- 2010-03-23 JP JP2012501278A patent/JP5774578B2/ja not_active Expired - Fee Related
- 2010-03-23 MX MX2011010061A patent/MX2011010061A/es active IP Right Grant
- 2010-03-24 TW TW99108736A patent/TWI470225B/zh not_active IP Right Cessation
-
2011
- 2011-08-11 IL IL214611A patent/IL214611A/en not_active IP Right Cessation
- 2011-09-16 CO CO11120337A patent/CO6450670A2/es not_active Application Discontinuation
- 2011-09-21 ZA ZA2011/06890A patent/ZA201106890B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2555858T3 (es) | 2016-01-11 |
| CA2756133A1 (en) | 2010-09-30 |
| KR20110138354A (ko) | 2011-12-27 |
| HUE026194T2 (en) | 2016-05-30 |
| BRPI1009892A2 (pt) | 2016-03-15 |
| TW201038943A (en) | 2010-11-01 |
| AU2010227611A1 (en) | 2011-08-25 |
| SG174507A1 (en) | 2011-10-28 |
| EP2411815A1 (en) | 2012-02-01 |
| JP5774578B2 (ja) | 2015-09-09 |
| JP2012521549A (ja) | 2012-09-13 |
| TWI470225B (zh) | 2015-01-21 |
| CO6450670A2 (es) | 2012-05-31 |
| EP2411815B1 (en) | 2015-11-11 |
| DK2411815T3 (en) | 2015-11-30 |
| NZ595290A (en) | 2012-09-28 |
| WO2010108908A1 (en) | 2010-09-30 |
| SG2014014021A (en) | 2014-07-30 |
| CN102362184A (zh) | 2012-02-22 |
| ZA201106890B (en) | 2012-06-27 |
| AU2010227611B2 (en) | 2014-05-29 |
| RU2542435C2 (ru) | 2015-02-20 |
| HK1161644A1 (en) | 2012-07-27 |
| US20120028279A1 (en) | 2012-02-02 |
| RU2011142612A (ru) | 2013-04-27 |
| CN102362184B (zh) | 2015-04-08 |
| IL214611A (en) | 2015-07-30 |
| IL214611A0 (en) | 2011-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| EA201490230A1 (ru) | Применение меченых ингибиторов hsp90 | |
| TR201907241T4 (tr) | IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2. | |
| MX2010005244A (es) | Composiciones y métodos para la terapia y el diagnóstico de influenza. | |
| EA201291336A1 (ru) | Замещенные 5-фтор-1н-пиразолопиридины и их применение | |
| ECSP19025350A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| AR098155A1 (es) | Métodos para diagnosticar y tratar trastornos eosinofílicos | |
| EA201100335A8 (ru) | Производные пурина для применения при лечении связанных с fab заболеваний | |
| EA201300558A1 (ru) | Соединения и способы для купирования боли | |
| EA201991484A1 (ru) | Лекарственные формы энзалутамида | |
| ZA201700196B (en) | Methods for treating high cardiovascular risk patients with hypercholesterolemia | |
| WO2014004990A3 (en) | Methods for determining drug efficacy using cereblon-associated proteins | |
| EA201590332A1 (ru) | Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа | |
| EA201690754A1 (ru) | Применение ингибитора pcsk9 для лечения гиперлипидемии | |
| EA201290836A1 (ru) | Связанные бис-арильные арилтриазолоны и их применение | |
| EA201101568A1 (ru) | Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta | |
| MY174894A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| BR112012026224A2 (pt) | métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia | |
| CY1120877T1 (el) | Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης | |
| CO7151543A2 (es) | Combinaciones terapéuticas y métodos para tratar el melanoma | |
| BR112013010136A2 (pt) | vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma | |
| MX2014014097A (es) | Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc). | |
| BR112014011488A2 (pt) | medicamento para tratamento terapêutico e/ou melhora de sépsis | |
| MX2014005749A (es) | Nanoportadores terapeuticos y/o de diagnostico, dirigidos a metaloproteinasa de matriz (mmp). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |